Alnylam Pharmaceuticals' Invested Capital rose 997.84% to $355.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.2 million, marking a year-over-year increase of 997.84%. This contributed to the annual value of $160.9 million for FY2024, which is 172.92% up from last year.
Per Alnylam Pharmaceuticals' latest filing, its Invested Capital stood at $355.2 million for Q3 2025, which was down 4.36% from $371.4 million recorded in Q2 2025.
In the past 5 years, Alnylam Pharmaceuticals' Invested Capital registered a high of $1.3 billion during Q2 2021, and its lowest value of -$408.1 million during Q2 2023.
Over the past 3 years, Alnylam Pharmaceuticals' median Invested Capital value was -$3.1 million (recorded in 2024), while the average stood at -$11.2 million.
Its Invested Capital has fluctuated over the past 5 years, first tumbled by 147.80% in 2023, then surged by 12,209.26% in 2025.
Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' Invested Capital stood at $1.3 billion in 2021, then crashed by 112.52% to -$158.2 million in 2022, then crashed by 39.45% to -$220.6 million in 2023, then surged by 172.92% to $160.9 million in 2024, then skyrocketed by 997.84% to $355.2 million in 2025.
Its Invested Capital was $355.2 million in Q3 2025, compared to $371.4 million in Q2 2025 and $233.5 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value